This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Clinical and Behavioral Findings

Jacques Bradwejn, MD, FRCPC; Diana Koszycki, MA; Christian Shriqui, MD, FRCPC

Arch Gen Psychiatry. 1991;48(7):603-610.

Abstract
• We studied the action of cholecystokinin tetrapeptide (CCK-4) in patients with panic disorder and normal controls. Subjects received, in random order, one injection of CCK-4 and one injection of placebo (saline) on two separate days in a double-blind crossover design. Two doses of CCK-4, 50 and 25 µg, were administered to two different samples of subjects. The panic rate with 50 µg of CCK-4 was 100% (12/12) for patients and 47% (7/15) for controls. The panic rate with 25 µg of CCK-4 was 91% (10/11) for patients and 17% (2/12) for controls. Nine percent of patients compared with 0% of controls panicked with placebo. These findings concur with previous reports of a panicogenic effect of CCK-4 and suggest that patients with panic disorder are more sensitive to the panicogenic effect of the peptide than are normal controls.

Author Affiliations
From the Psychopharmacology Division, St Mary's Hospital Center, and Department of Psychiatry, McGill University, Montreal, Quebec.

Footnotes
Accepted for publication October 17, 1990.

Read in part at the annual meetings of the American Psychiatric Association, San Francisco, Calif, May 11,1989, and the Society for Neuroscience, Phoenix, Ariz, November 2, 1989.

Reprint requests to Department of Psychiatry, St Mary's Hospital Center, 3830 Lacombe Ave, Montreal, Quebec, Canada H3T1M5 (Dr Bradwejn).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

CCK-4-induced anxiety but not panic is associated with serum brain-derived neurotrophic factor in healthy subjects
Maron et al.
J Psychopharmacol 2009;23:460-464.
ABSTRACT  

Altered Cerebral {gamma}-Aminobutyric Acid Type A-Benzodiazepine Receptor Binding in Panic Disorder Determined by [11C]Flumazenil Positron Emission Tomography
Hasler et al.
Arch Gen Psychiatry 2008;65:1166-1175.
ABSTRACT | FULL TEXT  

Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse.
Chen et al.
Proc. Natl. Acad. Sci. USA 2006;103:3881-3886.
ABSTRACT | FULL TEXT  

The Acute Antipanic Activity of Aerobic Exercise
Strohle et al.
Am. J. Psychiatry 2005;162:2376-2378.
ABSTRACT | FULL TEXT  

Central Cholecystokinin Activity in Irritable Bowel Syndrome, Panic Disorder, and Healthy Controls
Koszycki et al.
Psychosom. Med. 2005;67:590-595.
ABSTRACT | FULL TEXT  

Cognitive Modulation of the Endocrine Stress Response to a Pharmacological Challenge in Normal and Panic Disorder Subjects
Abelson et al.
Arch Gen Psychiatry 2005;62:668-675.
ABSTRACT | FULL TEXT  

The Effect of 5-Hydroxytryptophan on Cholecystokinin-4-Induced Panic Attacks in Healthy Volunteers
Maron et al.
J Psychopharmacol 2004;18:194-199.
ABSTRACT  

Anxiolytic Activity of Atrial Natriuretic Peptide in Patients With Panic Disorder
Strohle et al.
Am. J. Psychiatry 2001;158:1514-1516.
ABSTRACT | FULL TEXT  

A 28-Year-Old Woman With Panic Disorder
Gorman
JAMA 2001;286:450-457.
FULL TEXT  

Anxiolyticlike Effects of Atrial Natriuretic Peptide on Cholecystokinin Tetrapeptide-Induced Panic Attacks: Preliminary Findings
Wiedemann et al.
Arch Gen Psychiatry 2001;58:371-377.
ABSTRACT | FULL TEXT  

Response to Flumazenil in Women With Premenstrual Dysphoric Disorder
Le Mellédo et al.
Am. J. Psychiatry 2000;157:821-823.
ABSTRACT | FULL TEXT  

International Union of Pharmacology. XXI. Structure, Distribution, and Functions of Cholecystokinin Receptors
Noble et al.
Pharmacol. Rev. 1999;51:745-781.
ABSTRACT | FULL TEXT  

Effects of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological measures in healthy volunteers
Shlik et al.
J Psychopharmacol 1999;13:385-390.
ABSTRACT  

The New Biology of Gastrointestinal Hormones
REHFELD
Physiol. Rev. 1998;78:1087-1108.
ABSTRACT | FULL TEXT  

Decreased Brain GABAA-Benzodiazepine Receptor Binding in Panic Disorder: Preliminary Results From a Quantitative PET Study
Malizia et al.
Arch Gen Psychiatry 1998;55:715-720.
ABSTRACT | FULL TEXT  

Catecholamines and Pathogenesis in Panic Disorder
Heninger
Arch Gen Psychiatry 1998;55:522-523.
FULL TEXT  

Effects of Cholecystokinin Tetrapeptide on Respiratory Function in Healthy Volunteers
Bradwejn et al.
Am. J. Psychiatry 1998;155:280-282.
ABSTRACT | FULL TEXT  

Effect of Aging on Cholecystokinin-Induced Panic
Flint et al.
Am. J. Psychiatry 1998;155:283-285.
ABSTRACT | FULL TEXT  

Premenstrual Dysphoric Disorder and Response to Cholecystokinin-Tetrapeptide
Le Melledo et al.
Arch Gen Psychiatry 1995;52:605-606.
ABSTRACT  

The Panicogenic Effects of Cholecystokinin-Tetrapeptide Are Antagonized by L-365,260, a Central Cholecystokinin Receptor Antagonist, in Patients With Panic Disorder
Bradwejn et al.
Arch Gen Psychiatry 1994;51:486-493.
ABSTRACT  

The cholecystokinin hypothesis of panic and anxiety disorders: a review
Bradwejn et al.
J Psychopharmacol 1992;6:345-351.
ABSTRACT